WEBULL
News
TVGN
0.4217
-1.38%
-0.0059
Weekly Report: what happened at TVGN last week (1124-1128)?
Weekly Report · 4d ago
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
Benzinga · 11/28 09:49
Weekly Report: what happened at TVGN last week (1117-1121)?
Weekly Report · 11/24 10:38
Tevogen Bio Holdings Price Target Cut to $5.00/Share From $10.00 by D. Boral Capital
Dow Jones · 11/20 13:23
Tevogen Bio Holdings Is Maintained at Buy by D. Boral Capital
Dow Jones · 11/20 13:23
D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Lowers Price Target to $5
Benzinga · 11/20 13:13
Weekly Report: what happened at TVGN last week (1110-1114)?
Weekly Report · 11/17 10:39
*Tevogen Bio Holdings 3Q Loss/Shr 3c >TVGN
Dow Jones · 11/14 19:36
*Tevogen Bio Holdings 3Q Loss $5.73M >TVGN
Dow Jones · 11/14 19:34
Press Release: Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
Dow Jones · 11/14 19:32
Press Release: Tevogen Highlights Continued -2-
Dow Jones · 11/14 19:32
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
Barchart · 11/14 13:32
Weekly Report: what happened at TVGN last week (1103-1107)?
Weekly Report · 11/10 10:36
Tevogen Bio Expands Precision T Cell Therapy to Broader Patient Population
Reuters · 11/05 20:28
Tevogen announces clinical milestone in evolution of ExacTcell platform
TipRanks · 11/05 20:25
Tevogen Expands COVID-19 T Cell Therapy Reach With Multi-HLA Targeting, Expanding Patient Eligibility
Benzinga · 11/05 20:22
Tevogen Bio Expands Precision T Cell Therapy Eligibility With Multi-HLA Targeting
Reuters · 11/05 20:20
TEVOGEN REPORTS MAJOR CLINICAL MILESTONE: EXPANDS HLA COVERAGE OF ITS INVESTIGATIONAL PRECISION T CELL THERAPY FOR ACUTE AND LONG COVID
Reuters · 11/05 20:20
Tevogen Bio Says Stockholders' Deficit is Under $9.5M
Dow Jones · 11/03 20:16
Tevogen Clarifies GAAP-Reported Deficit, Plans Non-GAAP Metrics Disclosure Post Q3 2025 Filing
Benzinga · 11/03 19:55
More
Webull provides a variety of real-time TVGN stock news. You can receive the latest news about Tevogen Bio through multiple platforms. This information may help you make smarter investment decisions.
About TVGN
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.